Ivosidenib a ray of hope for rare biliary tract cancer?
22 Jul 2020
byAudrey Abella
Ivosidenib, a potent targeted inhibitor of mutated IDH1*, provided benefit for patients with IDH1-mutant, chemotherapy(CT)-refractory cholangiocarcinoma (CC), the ClarIDHy study has shown.